The ALOX12 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population derived from the HeLa cell line, in which the ALOX12 gene encoding arachidonate 12-lipoxygenase has been disrupted by CRISPR/Cas9-mediated gene targeting. This loss-of-function model enables the systematic study of 12-lipoxygenase activity in human cervical carcinoma cells, providing a genetically defined tool for dissecting eicosanoid-mediated signaling without residual enzyme expression. The polyclonal nature of the knockout pool reflects a heterogeneous mixture of cells harboring independent gene-disruption events, offering a robust representation of functional gene ablation while mitigating the risk of clonal artifacts often associated with single-cell-derived knockouts.
HeLa cells, the first immortalized human cell line, were derived from a cervical adenocarcinoma and have been a cornerstone of biomedical research for decades. These epithelial cells exhibit robust proliferation, high transfectability, and contain integrated human papillomavirus 18 (HPV18) sequences, which contribute to their transformed phenotype. HeLa cells are extensively employed in cancer biology, drug screening, and signal transduction studies due to their well-characterized genetic background and ease of manipulation. The cervical carcinoma origin makes HeLa an appropriate host for investigating genes implicated in epithelial tumorigenesis, particularly those involved in inflammation-driven cancer progression.
The ALOX12 gene product, arachidonate 12-lipoxygenase, catalyzes the stereospecific oxygenation of arachidonic acid at carbon 12 to generate 12-hydroperoxyeicosatetraenoic acid (12-HPETE), which is subsequently reduced to the bioactive mediator 12-hydroxyeicosatetraenoic acid (12-HETE). This eicosanoid functions through the GPR31 receptor and interfaces with multiple signaling cascades, including MAPK/ERK, NF-??B, and PI3K-AKT pathways. Upstream, ALOX12 expression is regulated by pro-inflammatory cytokines such as TNF-?? and growth factors like EGF, with transcription factors NF-??B and AP-1 playing central roles. Downstream, 12-HETE modulates the activity of MAPKs, AKT, Bcl-2, and MMP9, while also interacting with 14-3-3 proteins, GPX4, and cPLA2. Knockout of ALOX12 therefore blocks the arachidonic acid??12-HPETE??12-HETE metabolic axis, resulting in attenuated MAPK and NF-??B signaling, which collectively impair cellular proliferation, migration, and inflammatory gene expression.
In the HeLa cellular context, ALOX12 knockout eliminates the major 12-lipoxygenase pathway, rendering these cells devoid of 12-HETE biosynthesis. This disruption is particularly salient given that HeLa cells exhibit constitutive NF-??B activity and are responsive to eicosanoid-stimulated growth signals. The abrogation of ALOX12 is expected to compromise the ability of these cells to proliferate and migrate in response to inflammatory or growth factor stimuli, thereby providing a clean background for dissecting 12-HETE-dependent phenotypes. The polyclonal knockout approach ensures that no single integration-site effect biases the phenotypic readout, making it ideal for comparative studies with wild-type HeLa controls in assays that demand population-level analyses.
These ALOX12 knockout polyclonal cells are ideally suited for a breadth of functional investigations, including the role of 12-lipoxygenase in cancer cell proliferation using MTT or BrdU incorporation assays, migration studies via wound healing or Transwell assays, and inflammatory cytokine profiling by ELISA or multiplex bead arrays. They facilitate mechanistic dissection of arachidonic acid metabolism through LC-MS/MS quantification of 12-HETE and other eicosanoids, and enable validation of downstream signaling events such as phospho-ERK or phospho-AKT by Western blotting. In drug discovery, these cells serve as a critical control for LOX inhibitor selectivity screens and as a platform for evaluating anti-cancer compounds targeting eicosanoid pathways. For further information or technical assistance, please contact Ascent Research.
